NPPA issues final guidelines for Discontinuation of Scheduled Formulation

According to the final guidelines, any manufacturer who is intending to discontinue any scheduled formulation from the market, needs to issue a public notice in the newspaper

723
NPPA Price of drugs

Last Updated on August 16, 2020 by The Health Master

The National Pharmaceutical Pricing Authority (NPPA) has issued the final guidelines for discontinuation of manufacturing medicines, which are under price control regime. The issued guidelines are also applicable to scheduled medical devices which have been notified as a drug.

To download the NPPA Office Memorandum, click here

The NPPA website will be updated, based on the application filed by pharma companies and approved by the competent authority for discontinuation of scheduled formulations from the market on a monthly basis.

According to the final guidelines, any manufacturer who is intending to discontinue any scheduled formulation from the market, needs to issue a public notice in the newspaper, which varies based on the company’s moving annual turnover (MAT) value. If the MAT of the company is one per cent or less than one per cent then it has to be one newspaper, whereas, in the case of more than one per cent, the public notice has to be put in at least two national newspapers, one in English and one in Hindi. Besides this, the manufacturer also needs to intimate the government through form-IV at least six months prior to the intended date of discontinuation.

Also read: Action against 5 pharmacies for black marketing of Remdesivir

The final guidelines also inform that wherever the MAT of the company is more than one per cent or less than one per cent of total MAT value, it has to inform at least six months prior to the proposed/intended date of discontinuation and in such cases, it will be noted that without issuing any direction to the company, the case will be deemed approved. Whereas, in the case of more than one per cent of the total MAT value, the company will be directed with the approval of Chairman NPPA within a period of 60 days from the receipt of Form IV, intimating the request has been noted.

Besides this, the company will be directed to continue production/import and sale of the formulation for a period of up to 12 months from the date of issue of public notice.

In the final guidelines, the authority has mentioned that to ensure that there is no shortage of the formulation in the market, the government may direct the manufacturer of the scheduled formation to continue with the required level of production or import for a period not exceeding one year, from the intended date of discontinuation within a period of 60 days of receipt of such intimation.

It has directed that after getting the permission of discontinuation from the NPPA, the intending company should not reduce the level of production by more than 25 per cent of last year in each quarter.

It has also mentioned that wherever concerns regarding shortage are apprehended or a formulation is found to be critical for public health; based on the circumstances and also in cases where it is established that the company is intending to discontinue production/import and sale of a scheduled formulation and has already launched or intends to launch ‘a’ new drug to evade a price control; cases requiring continuance of production/ import and sale beyond 12 months or any other case related to this will be referred to the standing committee after the approval of NPPA’s Chairman.

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.